SCHEMBL4977541

SCHEMBL4977541

Cn1ccnc1-c1cc2nccc(Oc3ccc(NC(=O)c4ncc(-c5ccccc5)s4)cc3F)c2s1

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.69
KDR P35968 12/20 0.69
MST1R Q04912 10/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975121 0.91 MET (0.72) METKDRMST1R
SCHEMBL4975263 0.87 MET (0.68) METKDRMST1R
SCHEMBL4977779 0.87 MET (0.70) METKDRMST1R
SCHEMBL306762 0.85 MET (0.69) METKDRMST1R
SCHEMBL308075 0.85 MET (0.76) METKDRMST1R
SCHEMBL4301392 0.84 MET (0.70) METKDRMST1R
SCHEMBL14262952 0.84 MET (0.69) METKDRMST1R
SCHEMBL3560490 0.84 MET (0.86) METKDRMST1R
SCHEMBL307647 0.82 MET (0.71) METKDRMST1R
SCHEMBL18516121 0.82 MET (0.71) METKDRMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
WO-2007107005-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE, INC. (CA) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET MET 3/4885KDR 11/4885MST1R 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.